Published in Sci Rep on March 09, 2015
Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy. Sci Rep (2016) 0.78
Nano-enabled delivery of diverse payloads across complex biological barriers. J Control Release (2015) 0.76
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. Exp Cell Res (1965) 21.61
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res (1992) 9.02
The essence of senescence. Genes Dev (2010) 8.21
Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol (1993) 5.88
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer (2009) 5.02
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res (2007) 4.39
A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol (2001) 2.87
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res (2008) 2.38
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol (2009) 2.14
The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev (2007) 2.07
Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev (2008) 1.88
Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J (1957) 1.74
Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp Mol Pathol (2006) 1.69
Latent beta-transforming growth factor in nontransformed and Kirsten sarcoma virus-transformed normal rat kidney cells, clone 49F. Cancer Res (1984) 1.51
Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol (2013) 1.50
TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol (2008) 1.49
Endothelial cells require STAT3 for protection against endotoxin-induced inflammation. J Exp Med (2003) 1.49
Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother (2006) 1.19
Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia (1999) 1.11
Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Res (2002) 1.09
Role of TGF-beta in immune-evasion of cancer. Microsc Res Tech (2001) 1.05
Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol (1998) 0.98
Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today (1998) 0.97
Analysis of tumour cell composition in tumours composed of paired mixtures of mammary tumour cell lines. Br J Cancer (1987) 0.96
Genome-wide analysis of molecular changes in IL-12-induced control of mammary carcinoma via IFN-gamma-independent mechanisms. J Immunol (2004) 0.90
Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res (2000) 0.89
Immunoregulatory T cells: role and potential as a target in malignancy. Curr Oncol Rep (2008) 0.88
Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res (1999) 0.87
Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urol (1998) 0.86
Serum soluble Fas levels in ovarian cancer. Obstet Gynecol (2000) 0.83
Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients. Br J Cancer (1999) 0.79
Serum soluble Fas level for detection and staging of prostate cancer. Anticancer Res (2002) 0.78